Clinical, pathological and PAM50 gene expression features of HER2-low breast cancer
Autor: | Miguel Martín, Laia Paré, Barbara Adamo, Roberta Fasani, Blanca Gonzalez-Farre, Benedetta Conte, Giovanna Sabarese, Carlos H. Barrios, Fara Brasó-Maristany, Esther Sanfeliu, Mariavittoria Locci, Giuseppe Perrone, Francesca Zalfa, Esther Barnadas, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Ana Lluch, Maria Vidal, Joaquín Gavilá, Tomás Pascual, Aleix Prat, Francesco Schettini, Sabino De Placido, Patricia Villagrasa, Vicente Peg, Nuria Chic, Juan Miguel Cejalvo |
---|---|
Přispěvatelé: | Schettini, F., Chic, N., Braso-Maristany, F., Pare, L., Pascual, T., Conte, B., Martinez-Saez, O., Adamo, B., Vidal, M., Barnadas, E., Fernandez-Martinez, A., Gonzalez-Farre, B., Sanfeliu, E., Cejalvo, J. M., Perrone, G., Sabarese, G., Zalfa, F., Peg, V., Fasani, R., Villagrasa, P., Gavila, J., Barrios, C. H., Lluch, A., Martin, M., Locci, M., De Placido, S., Prat, A., Institut Català de la Salut, [Schettini F] Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Chic N] Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. [Brasó-Maristany F] Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. [Paré L] SOLTI Breast Cancer Research Group, Barcelona, Spain. [Pascual T] Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. [Conte B] Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. Department of Medical Oncology, Ospedale Policlinico San Martino, University of Genova, Genova, Italy. [Peg V] Vall d’Hebron Hospital Universitari, Barcelona, Spain. GEICAM, Grupo Español de Investigación en Cáncer de Mama, Madrid, Spain. [Fasani R] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES] Disease Article Càncer de mama 03 medical and health sciences 0302 clinical medicine Breast cancer Mama - Càncer Internal medicine Gene expression Cancer genomics Other subheadings::Other subheadings::/genetics [Other subheadings] Medicine High activity Pharmacology (medical) Radiology Nuclear Medicine and imaging skin and connective tissue diseases Gene Pathological neoplasms RC254-282 neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES] Her2 expression business.industry Otros calificadores::Otros calificadores::/genética [Otros calificadores] Investigative Techniques::Genetic Techniques::Gene Expression Profiling [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Neoplasms. Tumors. Oncology. Including cancer and carcinogens Translational research medicine.disease Expressió gènica 3. Good health ERBB2 Amplification técnicas de investigación::técnicas genéticas::perfiles de expresión génica [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] 030104 developmental biology 030220 oncology & carcinogenesis business |
Zdroj: | Dipòsit Digital de la UB Universidad de Barcelona Scientia NPJ Breast Cancer npj Breast Cancer, Vol 7, Iss 1, Pp 1-13 (2021) |
Popis: | Càncer de mama; Genòmica del càncer; Recerca translacional Cáncer de mama; Genómica del cáncer; Investigación traslacional Breast cancer; Cancer genomics; Translational research Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression. This work was supported by the grants from the European Union’s Horizon 2020 Research and Innovation Programme under Grant agreement No. 847912 (to A.P.), the Instituto de Salud Carlos III-PI16/00904 (to A.P.), Pas a Pas (to A.P.), Save the Mama (to A.P.), Breast Cancer Now-2018NOVPCC1294 (to A.P.), Fundación Científica Asociación Española Contra el Cáncer-Ayuda Postdoctoral AECC 2017 (to F.B.-M.), Fundación SEOM, Becas FSEOM para Formación en Investigación en Centros de Referencia en el Extranjero 2018 (to T.P.) and PhD4MD - Departament de Salut expedient SLT008/18/00122 (to N.C.). |
Databáze: | OpenAIRE |
Externí odkaz: |